Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema...
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get ...
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Maki...
Top Cities for Alpha-1 Antitrypsin Deficiency Clinical Trials
Alpha-1 Antitrypsin Deficiency clinical trials are recruiting across 18 cities. Here are the cities with the most active studies:
About Alpha-1 Antitrypsin Deficiency
Alpha-1 antitrypsin deficiency is a genetic condition that increases the risk of lung and liver disease due to low levels of the protective protein alpha-1 antitrypsin. It is one of the most common genetic causes of COPD. Treatment includes augmentation therapy and management of lung and liver symptoms.
Clinical trials are advancing new treatments for alpha-1 antitrypsin deficiency. Currently, 3 studies are recruiting a combined 395 participants across the United States. Research is being conducted by 2 organizations including Sanofi, Takeda.
2026 Alpha-1 Antitrypsin Deficiency Research Landscape
As of March 2026, the alpha-1 antitrypsin deficiency clinical trial landscape includes 3 actively recruiting studies across 18 cities in the United States. These studies are collectively seeking 395 participants, with an average enrollment target of 132 per study.
Research is being led by 2 different organizations, including Sanofi, Takeda.
Geographically, alpha-1 antitrypsin deficiency trials are most concentrated in Phoenix, Arizona (5 trials); Los Angeles, California (3 trials); Birmingham, Alabama (2 trials); Gainesville, Florida (2 trials); Indianapolis, Indiana (2 trials) and 7 other cities.
Featured Alpha-1 Antitrypsin Deficiency Studies
Highlighted recruiting studies for alpha-1 antitrypsin deficiency, selected by enrollment size and research scope.
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body (called pharmacodynamics), to learn if fazirsiran reduces other liver injury (inflammation) and the abnormal Z-AAT protein in the liver, to get informati...
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrh...
Frequently Asked Questions About Alpha-1 Antitrypsin Deficiency Clinical Trials
Are there alpha-1 antitrypsin deficiency clinical trials near me?
Yes, there are 3 alpha-1 antitrypsin deficiency clinical trials currently recruiting across 18+ cities in the United States, including Phoenix, Arizona; Los Angeles, California; Birmingham, Alabama. Browse the studies above to find one at a location convenient for you.
How do I join a alpha-1 antitrypsin deficiency clinical trial?
To join a alpha-1 antitrypsin deficiency clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are alpha-1 antitrypsin deficiency clinical trials free?
Yes, participation in alpha-1 antitrypsin deficiency clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of alpha-1 antitrypsin deficiency treatments are being studied?
Current alpha-1 antitrypsin deficiency clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 2 research organizations.
Is it safe to participate in alpha-1 antitrypsin deficiency clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov